SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-22-025691
Filing Date
2022-02-22
Accepted
2022-02-22 16:54:50
Documents
4

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm222155d8_defa14a.htm DEFA14A 41352
2 GRAPHIC tm222155d8_defa14aimg001.jpg GRAPHIC 4637
3 GRAPHIC tm222155d8_defa14aimg002.jpg GRAPHIC 183039
4 GRAPHIC tm222155d8_defa14aimg003.jpg GRAPHIC 139018
  Complete submission text file 0001104659-22-025691.txt   492742
Mailing Address 414 COMMERCE DRIVE STE 120 FORT WASHINGTON PA 19034
Business Address 25-28 NORTH WALL QUAY DUBLIN L2 D01 H104 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37558 | Film No.: 22659061
SIC: 2834 Pharmaceutical Preparations